Please login to the form below

Not currently logged in
Email:
Password:

Cytos Biotechnology

This page shows the latest Cytos Biotechnology news and features for those working in and with pharma, biotech and healthcare.

Alzheimer's disease pipeline takes multiple hits

Alzheimer's disease pipeline takes multiple hits

modulator EVP 0962 (EnVivo Pharmaceuticals); the metal protein-attenuating compound called PBT 2 (Prana Biotechnology); and ELND 005 (Speranza Therapeutics). ... Phase II agents include vanutide cridificar (Elan, Pfizer, Janssen Alzheimer Immunotherapy),

Latest news

  • Kicking the habit

    Vaccination route. It appears that vaccination could also be an option in modern day smoking cessation therapy, of which the most advanced are Nabi Biopharmaceuticals' NicVAX and Cytos Biotechnology's ... Cytos has completed a phase II study in 341

  • Silent, yet deadly

    CYT 006 AngQb, from Cytos Biotechnology, is another new therapeutic vaccine in development.

  • Deals in development

    been evaluated in patients with lung cancer, prostate cancer and ovarian cancer; and Cytos Biotechnology's NIC-002 ó a therapeutic vaccine for the potential treatment of nicotine dependency. ... The deal that brought NIC-002 to the Novartis portfolio

  • News in Brief, May 30, 2007

    Cytos reports results from a phase I/IIa psoriasis vaccine study. Switzerland-headquartered Cytos Biotechnology has reported results from a placebo-controlled, double-blind combined phase I/IIa study with ... Cangene manufactures VIG in its Winnipeg

  • News in brief, May 02, 2007

    Cytos Biotechnology enters nicotine vaccine agreement with Novartis. Swiss biotechnology company, Cytos, has entered into an exclusive global commercial license agreement with Novartis, to develop, manufacture and commercialise CYT002-NicQb, a

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Exclusive commercial licence. 165. Cytos Biotechnology. Checkmate Pharmaceuticals. CYT 003 and VLP [virus like particle] platform in oncology.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Corporate acquisition. 545. Cytos Biotechnology/ OnCore. Access to virus like particle (VLP) platform for the treatment and prevention of hepatitis B with an option to other viral diseases.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Dr Christian Itin joins Cytos Biotechnology as CEO Dr Christian Itin joins Cytos Biotechnology as CEO

    He moves to the Swiss biotech from Micromet. Swiss biotech company Cytos Biotechnology has appointed Dr Christian Itin to be its new CEO. ... We believe with his experience and skills that he is well positioned to shape Cytos' future.” .

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....